Table 1.
Baseline demographics and disease characteristics of patients (N = 17)
| Characteristic | 160 mg QD, N = 3 | 320 mg QD, N = 3 | 480 mg QD, N = 4 | 300 mg BID, N = 7 | Total N = 17 |
|---|---|---|---|---|---|
| Age | |||||
| Median, years (range) | 70.0 (62‐70) | 72.0 (68‐72) | 74.5 (68‐79) | 71.0 (37‐80) | 70.0 (37‐80) |
| <65 y, n (%) | 1 (33.3) | 0 | 0 | 1 (14.3) | 2 (11.8) |
| ≥65 y, n (%) | 2 (66.7) | 3 (100.0) | 4 (100.0) | 6 (85.7) | 15 (88.2) |
| Sex | |||||
| Male, n (%) | 3 (100.0) | 1 (33.3) | 1 (25.0) | 3 (42.9) | 8 (47.1) |
| Female, n (%) | 0 | 2 (66.7) | 3 (75.0) | 4 (57.1) | 9 (52.9) |
| Histologic subtype, n (%) | |||||
| Non−GCB DLBCL | 0 | 0 | 2 (50.0) | 2 (28.6) | 4 (23.5) |
| DLBCL | 0 | 0 | 0 | 1 (14.3) | 1 (5.9) |
| MCL | 1 (33.3) | 2 (66.7) | 1 (25.0) | 0 | 4 (23.5) |
| FL | 0 | 1 (33.3) | 1 (25.0) | 3 (42.9) | 5 (29.4) |
| WM | 1 (33.3) | 0 | 0 | 1 (14.3) | 2 (11.8) |
| CLL | 1 (33.3) | 0 | 0 | 0 | 1 (5.9) |
| Relapsed or refractory after the latest treatment, n (%) | |||||
| Relapsed | 0 | 2 (66.7) | 2 (50.0) | 4 (57.1) | 8 (47.1) |
| Refractory | 3 (100.0) | 1 (33.3) | 2 (50.0) | 3 (42.9) | 9 (52.9) |
| Prior therapies, n (%) | |||||
| Prior rituximab | 2 (66.7) | 3 (100.0) | 4 (100.0) | 7 (100.0) | 16 (94.1) |
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; non−GCB DLBCL, non−germinal center B‐cell‐like diffuse large B‐cell lymphoma; WM, Waldenström's macroglobulinemia.